Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma (Q38458593)

3 September 2017

title

Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma (English)

1 reference

3 September 2017

Kilpatrick SE

1

1 reference

3 September 2017

Geisinger KR

2

1 reference

3 September 2017

King TS

3

1 reference

3 September 2017

Sciarrotta J

4

1 reference

3 September 2017

Ward WG

5

1 reference

3 September 2017

Gold SH

6

1 reference

3 September 2017

Bos GD

7

1 reference

3 September 2017

publication date

1 December 2001

1 reference

3 September 2017

1 reference

3 September 2017

volume

14

1 reference

3 September 2017

issue

12

1 reference

3 September 2017

page(s)

1277-1283

1 reference

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

7 January 2021

C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

7 January 2021

Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

7 January 2021

Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880474

7 January 2021

10.1038/MODPATHOL.3880474

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1005696723

0 references

1 reference